Closing the Scale-Up Gap: Manufacturing Challenges and Innovations in Cell and Gene Therapy
Key Insights
Cell and gene therapy (search) manufacturing faces critical scale-up barriers, including transient transfection limitations, donor variability, and stringent supply-chain logistics that delay clinical translation.
Automated closed-system platforms, stable producer cell lines, and digital quality management systems are emerging as key technologies to improve reproducibility and reduce costs.
Experts emphasize that commercial manufacturing strategy must begin at the Target Product Profile stage, long before clinical trials, to avoid costly process changes later.
The transition from laboratory-scale development to robust, GMP-compliant commercial manufacturing remains one of the principal barriers to broader clinical adoption of cell and gene therapies (CGT). While several products have reached commercialization, advancing new therapies into late-stage trials and routine clinical practice continues to challenge developers, who must consistently deliver product quality, safety, potency, and regulatory compliance while accommodating increasing demand and reducing production costs.
The Root of Manufacturing Complexity
Cell-based therapies, which use cells such as mesenchymal stem cells (MSCs), and gene-based therapies, which rely on vectors such as adeno-associated viral vectors (search) (AAV) or lentiviral vectors (search) (LVs), each present distinct manufacturing hurdles. For cell-based approaches, key challenges include maintaining source material under appropriate conditions, eliminating contamination, and simplifying multistep procedures. For gene-based therapies, efforts are ongoing to develop stable producer cell lines that do not require plasmid DNA for vector production and that maximize AAV and LV titers while minimizing costs.
Manufacturing sufficient quantities of recombinant AAV products to meet rapidly expanding clinical demand remains a bottleneck. Platforms dependent on transient transfection for vector generation are often limited by scale and cell density, requiring large amounts of transfection reagents and genetic material that drive up production costs and introduce batch-to-batch variability. Autologous cell therapy approaches using blood or stem cells are difficult to transfect, and isolating cells from patients or matched donors can yield highly variable starting material.
"One of the most common mistakes is focusing on getting a product into the clinic without thinking about what happens afterwards," said Drew Hope, Senior Bio Manufacturing & Compliance Consultant and UK Qualified Person at eXmoor Pharma (search). "Many developers transfer a research or preclinical process into a GMP environment to generate clinical data as quickly as possible. While that can help achieve an early milestone, it can also result in a process that is difficult to scale, control or commercialise."
The Scale-Up Gap in Bioprocessing
Processes optimized at laboratory scale often fail at commercial scale. Suspension transient transfection enables rapid implementation but is challenging to scale and requires expensive raw materials such as plasmids and polyethylenimine. Baculovirus expression vector systems enable larger volumes than mammalian cell culture platforms, yet scientists face difficulties related to the genetic instability of recombinant baculovirus and safety concerns regarding helper-virus impurities.
Producer cell line systems represent a more scalable manufacturing platform capable of commercial-scale production at bioreactor scales exceeding 2,000 liters. However, development of stable producer cell lines requires considerable time, specialized expertise, and GMP-qualified cell banks. Emerging inducible producer cell line technologies may further increase volumetric productivity by separating cell growth from vector production.
Supply-chain logistics present additional obstacles. While blood products have shelf lives that allow for modest delays in distribution, the transit window for CGTs and precursor material is more stringent. Long-term inventory management remains largely dependent on cryopreservation, yet few clinics possess liquid nitrogen storage or −80°C freezers.
Hope emphasized that manufacturability, process robustness, and quality requirements are sometimes considered too late. "Decisions around raw materials, analytical methods and process controls can have long-term consequences that only become apparent as development progresses," he noted. "Generating a GMP batch and developing a GMP-ready process are not necessarily the same thing."
Technologies Closing the Gap
Automated and closed-system manufacturing technologies are playing an increasingly important role in overcoming scalability challenges. Traditional droplet-based flow sorting techniques are manual, open, labor-intensive, and highly technique-sensitive, making them unsuitable for commercial manufacture of thousands of doses per year. Manufacturers are increasingly adopting automated platforms that incorporate artificial intelligence, digital twins, and advanced image-processing technologies to improve reproducibility and reduce operator-dependent variability.
Several commercially available platforms—including modular closed bioreactor systems, hollow-fiber expansion systems, automated cell processing workstations, and configurable microfactory platforms—are designed to standardize manufacturing processes while supporting decentralized production under GMP conditions. Self-contained microfactory systems use proprietary environmental controls, in situ sensors, and reconfigurable isolators to support multiple manufacturing layouts while minimizing contamination risks.
Digital manufacturing technologies are also transforming CGT production. Electronic quality management systems, real-time process monitoring, advanced analytics, and data-driven process control improve batch consistency, reduce documentation burdens, enhance traceability, and facilitate regulatory compliance throughout the manufacturing lifecycle.
"Automation remains one of the most significant trends across the sector," Hope observed. "Developers are increasingly looking for ways to reduce operator dependency, improve consistency, and lower manufacturing costs."
Regulatory and Quality Considerations
CGT manufacturing must comply with stringent regulatory requirements to ensure product safety, efficacy, and consistency. Quality control extends throughout the manufacturing process and encompasses cell processing, viral vector production, reagent preparation, and final product testing under aseptic conditions. Critical quality attributes include product identity, potency, purity, sterility, viability, vector genome concentration, residual host-cell DNA, residual proteins, and viral contamination.
As manufacturing processes evolve during clinical development and commercial scale-up, demonstrating comparability following process modifications becomes a major regulatory challenge. Manufacturers must validate that changes to production platforms, raw materials, equipment, manufacturing sites, or production scale do not adversely affect product quality, safety, potency, or clinical performance.
Beyond technical hurdles, manufacturers frequently encounter workforce shortages, limited GMP expertise, funding constraints for early-stage developers, and increasingly stringent regulatory documentation requirements. Some commercial manufacturing facilities remain underused due to high operating costs and shortages of experienced personnel, whereas academic and large pharmaceutical GMP facilities often operate near full capacity.
Strategic Planning for Commercial Reality
Hope stressed that the starting point for any development program should be a Target Product Profile that defines what the eventual commercial product is intended to look like. "That does not mean every manufacturing decision needs to be fixed before clinical development begins, but it does provide a framework for making better decisions throughout development," he explained.
He also highlighted the value of early Cost of Goods analysis, which can help identify which parts of a process are likely to become major cost drivers and where development effort is likely to have the greatest impact. "Programmes are most successful when speed, quality and cost are treated as interconnected considerations rather than competing priorities."
Looking ahead, future advances in CGT manufacturing are expected to combine closed-system automation, decentralized or point-of-care manufacturing, artificial intelligence-assisted process control, standardized raw materials, stable producer cell technologies, and advanced analytics. Continued collaboration among academic institutions, manufacturers, technology developers, regulators, and funding organizations will be essential for expanding manufacturing capacity, developing a skilled workforce, reducing production costs, and accelerating patient access to these life-changing therapies.